The treatment groups were: a) Control (100 μl DMEM), to challenge with B16 tumor; b) Control-bis (100 μl DMEM), to challenge with 3LL tumor; c) B16-GMCSF+B7.2/40, employing 40.000 B16 selected cells per dose, in 100 μl DMEM; d) B16-GMCSF+B7.2/80, the same as before but with 80.000 B16 selected cells ; e) B16-GMCSF+B7.2/80 + 3LL, each dose being 80.000 B16 selected cells and 320.000 irradiated 3LL cells, with B16 tumor challenge; f) B16-GMCSF+B7.2/80+3LL, the same as before but with 3LL tumor challenge. Here, CD86 is linked to neoplasm.